

Pulmonary Arterial Hypertension Therapeutics Pipeline Industry H1 2016

The report provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

PUNE, INDIA, May 3, 2016 /EINPresswire.com/ -- The report "[Pulmonary Arterial Hypertension - Pipeline Review, H1 2016](#)" provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.

Complete Report Details Available at <https://www.wiseguyreports.com/reports/443148/pulmonary-arterial-hypertension-pipeline-review-h1-2016> .



This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Inquire more about this report at <https://www.wiseguyreports.com/enquiry/443148/pulmonary-arterial-hypertension-pipeline-review-h1-2016> .

Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development
APT Therapeutics, Inc.
Arena Pharmaceuticals, Inc.
Asahi Kasei Pharma Corp.

Ascendis Pharma A/S
Bial - Portela & Ca, S.A.
Bristol-Myers Squibb Company
Carolus Therapeutics, Inc.
Celsion Corporation
Complexa, Inc.
Corridor Pharmaceuticals Inc.
Cytokinetics, Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Insmmed Incorporated
INVENT Pharmaceuticals, Inc.
Johnson & Johnson
Kowa Company, Ltd.
Mallinckrodt Plc
Mezzion Pharma Co. Ltd.
miRagen Therapeutics, Inc.
Morphogen-IX Limited
Nippon Kayaku Co., Ltd
Nippon Shinyaku Co., Ltd.
Novartis AG
Peloton Therapeutics, Inc.
PharmaIN Corporation
PhaseBio Pharmaceuticals, Inc.
Pluristem Therapeutics Inc.
Proteo, Inc.
Pulmokine, Inc.
Reata Pharmaceuticals, Inc.
Respira Therapeutics, Inc.
Selten Pharma, Inc
Silence Therapeutics Plc
SteadyMed Therapeutics, Inc.
Suda Ltd
Toray Industries, Inc.

Get a sample copy at https://www.wiseguyreports.com/sample_request/443148/pulmonary-arterial-hypertension-pipeline-review-h1-2016 .

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension
- The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial

Hypertension

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Order a Purchase Report Copy @

https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=443148 .

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

16468459349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.